Cargando…

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

Ebola virus infection is a highly lethal disease for which there are no effective therapeutic or preventive treatments. Several vaccines have provided immune protection in laboratory animals, but because outbreaks occur unpredictably and sporadically, vaccine efficacy cannot be proven in human trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sullivan, Nancy J., Martin, Julie E., Graham, Barney S., Nabel, Gary J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097244/ https://www.ncbi.nlm.nih.gov/pubmed/19369954 http://dx.doi.org/10.1038/nrmicro2129

Ejemplares similares

Immunopathology of highly virulent pathogens: insights from Ebola virus
por: Zampieri, Carisa A, et al.
Publicado: (2007)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
por: Sullivan, Nancy J., et al.
Publicado: (2003)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs
por: Sullivan, Nancy J, et al.
Publicado: (2006)

Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration “Animal Rule”
por: Tsai, Chia-Wei, et al.
Publicado: (2015)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Ebanga™: The most recent FDA-approved drug for treating Ebola
por: Taki, Elahe, et al.
Publicado: (2023)

Amendments to the Financial Rules approved by the Finance Committee
por: European Organization for Nuclear Research
Publicado: (1955)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
por: Azizi, Hiva, et al.
Publicado: (2023)

Frequentist rules for regulatory approval of subgroups in phase III trials: A fresh look at an old problem
por: Edgar, K, et al.
Publicado: (2021)

Expedited regulatory product approval in the time of COVID-19
por: Novack, Gary D.
Publicado: (2022)

Modifications to the Staff Rules and Regulations concerning the process for approving amendments to the Staff Rules and Regulations
Publicado: (2022)

A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus
por: Ekins, Sean, et al.
Publicado: (2014)

Next-generation influenza vaccines: opportunities and challenges
por: Wei, Chih-Jen, et al.
Publicado: (2020)

Author Correction: Next-generation influenza vaccines: opportunities and challenges
por: Wei, Chih-Jen, et al.
Publicado: (2020)

Binding corporate rules: fixing the regulatory patchwork of data protection
por: Moerel, Elise Marie Leonore
Publicado: (2011)

Gene therapy for cancer: regulatory considerations for approval
por: Husain, S R, et al.
Publicado: (2015)

On the Regulatory Approval Pathway of Biosimilar Products
por: Wang, Jun, et al.
Publicado: (2012)

Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection
por: Veljkovic, Veljko, et al.
Publicado: (2015)

Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection
por: Tshiani Mbaya, Olivier, et al.
Publicado: (2021)

High-speed Ebola vaccine protects monkeys
Publicado: (2013)

Experimental inoculation of plants and animals with Ebola virus.
por: Swanepoel, R, et al.
Publicado: (1996)

Rules of the Staff Insurance Scheme 1976 Approval of Final Drafting Amendments
Publicado: (1977)

Rules of the staff insurance scheme 1976 - Approval of final drafting amendments
Publicado: (1977)

A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs
por: O′Hagan, Steve, et al.
Publicado: (2014)

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection
por: Marzi, Andrea, et al.
Publicado: (2016)

Design of universal Ebola virus vaccine candidates via immunofocusing
por: Xu, Duo, et al.
Publicado: (2023)

Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers()
por: Penny, Christopher J., et al.
Publicado: (2019)

The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
por: Jasenosky, Luke D., et al.
Publicado: (2019)

Regulatory approval for COVID-19 across the globe
por: Mahalmani, Vidya, et al.
Publicado: (2020)

Regulatory approval pathway for COVID-19 vaccine in USA, Europe and India
por: Narasimhan, Jaipratap, et al.
Publicado: (2023)

Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective
por: Sun, Wellington
Publicado: (2023)

Enhanced Protection against Ebola Virus Mediated by an Improved Adenovirus-Based Vaccine
por: Richardson, Jason S., et al.
Publicado: (2009)

Animal Simples Approved for Modern Uses of Cure
Publicado: (1900)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Animal models for Ebola and Marburg virus infections
por: Nakayama, Eri, et al.
Publicado: (2013)

Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine
por: Wong, Gary
Publicado: (2019)

Regulatory approval of new medical devices: cross sectional study
por: Marcus, Hani J, et al.
Publicado: (2016)

Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection
por: Qiu, Xiangguo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_d4g8lcstscap085pq2bv444o5m